ACKR3 and prostate carcinoma: Therefore, we developed a polyclonal antibody (i.e., pAbCXCR7) against the CXCR7 C-terminus (i.e., residues 348–362) to use in exploring, in depth, the subcellular localization and expression of this protein in prostate-cancer cells.